ARTICLE | Clinical News
CETi-1: Completed Phase I trial enrollment
February 7, 2000 8:00 AM UTC
Avant Immunotherapeutics Inc. (AVAN), Needham, Mass. Product: CETi-1 Business: Cardiovascular Therapeutic category: Metabolism Target: Cholesteryl ester transfer protein (CETP) Description: Vaccine t...